The CDMO’s boost in production will be centered around pharmaceutical products.
In an effort to surge its pharmaceutical production capabilities by as much as 30% across its European facilities, Berry Global Group, Inc., a contract development and manufacturing organization (CDMO) and provider of packaging solutions, is investing in a surplus of assets and manufacturing services.
With locations in Offranville, France; Osnago, Italy; and Sirone, Italy—which happen to be in close proximity to pharmaceutical manufacturing and filling site hubs—the company is able to assist with providing quick response times. Further investing in these sites, Berry says, helps boost supply chain reliability, which ultimately product availability, a necessity when constantly having to meet demand.
And after the unveiling of its production plant and healthcare center of excellence in Bangalore, India, these recent financial commitments reiterate Berry’s belief in providing packaging and drug delivery devices that are capable of improving the patient experience.
“As pharmaceutical innovations progress, so should the packaging and support that delivers each dose. Berry Global is here to provide that expertise in the creation of patient-centered packages and drug delivery device design,” said Walid Hamza, Berry Global’s EVP of global healthcare. “We continue to invest in the latest healthcare technologies to help our customers offer patients a safe and improved experience with every dose.”
The Offranville site focuses on the manufacture of standard and custom solutions for pharmaceutical packaging and drug delivery devices, such as ophthalmic and nasal products. The site has made various investments, such as a new cleanroom production that meets the ISO7 standard. As for Berry’s Osnago plant, it produces throat spray actuators, while the Sirone site creates the actual throat spray actuator bottles.
Reference
Berry Global Invests to Increase Production Capacity for Healthcare Products. Berry Global Group, Inc. April 18, 2024. Accessed April 29, 2024. https://www.berryglobal.com/en/news/articles/berry-global-invests-to-increase-production-capacity-for-healthcare-products
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.